Genmab — Februar 2021
-
Nu er Genmab heldigvis super likvid, så mon ikke de beholder den..;-)
-
Aab - det er jo netop det, der er humlen - de likvide bliver solgt
-
Min forudsigelse fra i går holdt ikke helt stik..22 ned.
-
Er vi ikke ved at få etableret, at GEN ikke er en af de defensive aktier...
-
Den er ihvertfald ikke i offensiven..:-D
-
US begynder ligefremt at se fornuftig ud
-
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab https://ir.genmab.com/news-releases/news-release-details/grant-restricted-stock-units-management-and-employees-and-grant
-
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons https://ml-eu.globenewswire.com/Resource/Download/1404eba2-350b-402d-bf81-62f4b57637b4
-
12077 aktier til Jan
-
Lidt interessant læsning https://www.marketscreener.com/quote/stock/GENMAB-A-S-63733191/consensus/
-
@AaB 16.40: En Biotech ETF skal indeholde biotech aktier og hvis de sælger ud i de illikvide skal de vel købe op i likvide eller ligge kontant i ETFen for de penge de får ind for de illikvide salg. Skal ikke kunne sige om det kommer til at gå ud over Genmab men konsensue target er omkring 2400 p.t så nok begrænset hvor mange Genmabber Ark invest, Blackrock, Vanguard og ander ETF udbyddere vil sælge. Det vil også et sats hvis Vanguard eller Ark sælger deres genmabber for at ligge kontant
-
-
Vil det kommende aktietilbagekøb også dræne kursen, når disse dækker warrants. Genmab køber i dag til kurs x, pengene x forlader kassen, kursen falder, aktien afnoteres ikke, men leveres en dag hvor X er lavere end dagskursen ved exercise?
-
God morgen.
-
Stock ull 07.03 - tænker du mener gns kursmål, når du skriver 2.400. Enten er det en skrivefejl eller også bare ikke opdateret. Med alle de nye target er det gennemsnitlige kursmål gået ned på ca 2.550 - altså faldet over 150. Stadig en vurdering langt over dagens kurs https://www.proinvestor.com/boards/89730/Kursmaal-Genmab#91346
-
The share is getting closer to its long-term support in weekly data, at DKK 1913.5, which offers good timing for buyers.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The group usually releases upbeat results with huge surprise rates.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind